“The NRDL inclusion of AUGTYRO significantly expands access to patients living with ROS1+ NSCLC in China to a new treatment option with promising durability. We look forward to launching AUGTYRO by ...
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor ...
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...
Despite the “unfortunate” failure, William Blair analysts do not believe that the utreloxastat readout will heavily affect ...
Trump is rounding out his health cabinet with another controversial figure: one of the authors of the Great Barrington ...
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--$ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic ...
The live and archived webcast of the presentations can be accessed in the Investors section of the Company’s website here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback